Arbutus Biopharma's Imdusiran Gets FDA Fast Track Designation

Arbutus Biopharma Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational therapy, imdusiran. This designation is for the treatment of chronic hepatitis B, a serious condition with unmet medical needs. The Fast Track program aims to facilitate the development and expedite the review process for such therapies, potentially accelerating imdusiran's path to market.